Anti-Human FGF23 Recombinant Antibody (Burosumab) (CAT#: TAB-010ML)
Recombinant monoclonal antibody to FGF23. Burosumab is a human monoclonal antibody that can be potentially used in the treatment of Dermatological genetic disorders, Hypophosphatemia, Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS), X-linked (Hereditary hypophosphatemic rickets), Osteomalacia, oncogenic.
Specific Inquiry
PK
Figure 1 Effects of Burosumab on Pharmacodynamic Variables.
All serum and urine samples were obtained during fasting. A significant mean increase from baseline to week 40 in serum phosphorus level (Panel A), the renal tubular phosphate reabsorption (expressed as the ratio of the maximum rate of tubular reabsorption of phosphate to the glomerular filtration rate) (Panel B), and serum 1,25-dihydroxyvitamin D level (Panel C) was seen among the 26 patients in each group (P<0.001).
Carpenter, T. O., Whyte, M. P., Imel, E. A., Boot, A. M., Högler, W., Linglart, A.,... & Skrinar, A. (2018). Burosumab therapy in children with X-linked hypophosphatemia. New England Journal of Medicine, 378(21), 1987-1998.
PK
Figure 2 Effect of burosumab on pharmacodynamic markers.
The dashed lines in panels A and B are the lower and upper limits of normal. Arrows indicate administration of study drug (burosumab or placebo). 1,25(OH)2D = 1,25 dihydroxyvitamin D; TmP/GFR = ratio of the maximum rate of tubular phosphate reabsorption to the glomerular filtration rate.
Insogna, K. L., Briot, K., Imel, E. A., Kamenický, P., Ruppe, M. D., Portale, A. A.,... & Imanishi, Y. (2018). A randomized, double‐blind, placebo‐controlled, phase 3 trial evaluating the efficacy of burosumab, an anti‐FGF23 antibody, in adults with X‐linked hypophosphatemia: week 24 primary analysis. Journal of Bone and Mineral Research, 33(8), 1383-1393.
FuncS
Figure 3 Effect of burosumab on participant‐reported outcomes.
Data are expressed as least squares mean change from baseline ± standard error. BPI = Brief Pain Inventory; WOMAC = Western Ontario McMaster Universities Osteoarthritis Index.
Insogna, K. L., Briot, K., Imel, E. A., Kamenický, P., Ruppe, M. D., Portale, A. A.,... & Imanishi, Y. (2018). A randomized, double‐blind, placebo‐controlled, phase 3 trial evaluating the efficacy of burosumab, an anti‐FGF23 antibody, in adults with X‐linked hypophosphatemia: week 24 primary analysis. Journal of Bone and Mineral Research, 33(8), 1383-1393.
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Human
- Type
- IgG1, κ
- Specificity
- Human FGF23
- Species Reactivity
- Human
- Applications
- ELISA, IHC, FC, IP, IF, Inhib, PK, FuncS
- Conjugate
- Unconjugated
- CAS
- 1610833-03-8
- Generic Name
- Burosumab
- UNII
- G9WJT6RD29
- Related Disease
- Dermatological genetic disorders, Hypophosphatemia, Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS), X-linked (Hereditary hypophosphatemic rickets), Osteomalacia, oncogenic
Product Property
- Purity
- > 95% as determined by SDS-PAGE
- Storage
- Store at -20°C for long-term storage. Avoid freeze/thaw cycles.
Applications
- Application Notes
- The FGF23 antibody has been reported in applications of ELISA, IHC, FC, IP, IF, Inhib, PK, FuncS.
Target
Related Resources
Please refer to Burosumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Burosumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Burosumab"
Afuco™ Anti-FGF23 ADCC Recombinant Antibody (Burosumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to FGF23. Burosumab is a human monoclonal antibody that can be potentially used in the treatment of Dermatological genetic disorders, Hypophosphatemia, Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS), X-linked (Hereditary hypophosphatemic rickets), Osteomalacia, oncogenic.
See other products for "FGF23"
Recombinant Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-2776z | Mouse Anti-FGF23 Recombinant Antibody (clone 33H1) | WB, ELISA, ICC, IHC | Mouse IgG |
| HPAB-0207-YC | Human Anti-FGF23 Recombinant Antibody (HPAB-0207-YC) | ELISA, FuncS | Human IgG |
| MOB-145YJL | Rat Anti-FGF23 Recombinant Antibody (clone CBF850) | WB, ELISA | Rat IgG2a |
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0207-YC-S(P) | Human Anti-FGF23 Recombinant Antibody; scFv Fragment (HPAB-0207-YC-S(P)) | ELISA, FuncS | Human scFv |
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0207-YC-F(E) | Human Anti-FGF23 Recombinant Antibody; Fab Fragment (HPAB-0207-YC-F(E)) | ELISA, FuncS | Human Fab |
ADCC Enhanced Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AFC-TAB-010ML | Afuco™ Anti-FGF23 ADCC Recombinant Antibody (Burosumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, Inhib | ADCC enhanced antibody |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TAB-010ML. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.